Explore how Moderna's (MRNA) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

The article " Moderna: A Generational Opportunity for Investors in 2025 " first appeared on MarketBeat.

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...